The Lung Cancer Channel on VJOncology is supported by Janssen Oncology (a pharmaceutical company of Johnson & Johnson), Takeda and AstraZeneca. These supporters have no influence over the production of the content.
Cancers that are diagnosed earlier in the disease course, when they’re smaller in size and haven’t spread, are more treatable. More than 80% of lung cancer patients will survive at least 1 year post-diagnosis, if they are diagnosed earlier. Therefore, early diagnosis is essential for improving outcomes for patients and prolonging the time to later stage disease.
One method which has been used for other types of cancer, is screening. There has been extensive research in recent years, investigating the value of screening for lung cancer. One such study, NELSON, showed that lung in patients who are high-risk, lung cancer mortality was significantly lower among those who underwent CT screening compared with those who didn’t. The implementation of a wide-scale screening programme is still up for debate in many countries.View overview page